Patients who had positive ctDNA tests after surgery were almost twice as likely to be alive at 3 years if they received ...

New data from two studies presented at ASCO GI 2025 demonstrated that ctDNA testing could predict recurrence risk in ...

Overall, the platform’s capability to detect ultra-low ctDNA levels holds promise for advancing personalized medicine in early-stage lung cancer.

Analysis of serum and urine miRNAs as biomarkers of cancer cachexia in pancreatic cancer. This is an ASCO Meeting Abstract from the 2025 ASCO Gastrointestinal Cancers Symposium. This abstract does not ...

“We look forward to continuing our work with the TRACERx team on the broader clinical performance of ctDNA testing in early stage lung cancer. We expect the subsequent publication of those ...

An ultrasensitive blood test detecting low levels of ctDNA could help to improve disease stratification in early-stage lung adenocarcinoma.

For those who had negative ctDNA tests, there was no significant difference between those taking celecoxib versus placebo.